

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-201) CEVOSTAMAB
 PRONUNCIATION se vos' ta mab
 THERAPEUTIC CLAIM Treatment of cancer

CHEMICAL NAMES

1. Immunoglobulin G1 [300-glycine,369-tryptophan], anti-(human Fc receptor-like protein FCRL5) (human-*Mus musculus* monoclonal KFCR8534A γ 1-chain), disulfide with human-*Mus musculus* monoclonal KFCR8534A κ -chain, dimer with immunoglobulin G1 [299-glycine,368-serine,370-alanine,409-valine], anti-(human CD3 antigen) (human-*Mus musculus* monoclonal HCDT4425A γ 1-chain), disulfide with human-*Mus musculus* monoclonal HCDT4425A κ -chain (Source: CAS)
2. Immunoglobulin G1-kappa, anti-(*Homo sapiens* Fc receptor-like protein 5, *FCRL5* (BXMAS1, Fc receptor homolog 5, Immune receptor translocation-associated protein 2, CD307e-antigen)) and anti-(*Homo sapiens* T-cell surface glycoprotein CD3 epsilon chain, *CD3E* (Leu-4 epsilon chain, CD3e-antigen)), monoclonal antibody, bispecific tetravalent; γ 1 heavy chain anti *FCRL5* (1-450) [VH (*Mus musculus* IGHV2-4*01 (77%) –(IGHD)-IGHJ3*01 (91%)/*Homo sapiens* IGHV4-4*08 (73%) –(IGHD)-IGHJ5*01 (86%)] [8.7.14] (1-120) -*Homo sapiens* IGHG1*03 {CH1[R⁹⁷>K(217)], CH2[N⁶⁷>G(300)], CH3[T²⁶>W(369)]} (121-450) (223-214')-disulfide with κ light chain anti *FCRL5* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (83%) –IGKJ2*01 (92%)] [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')], (229-228":232-231")-bisdisulfide with γ 1 heavy chain anti *CD3* (1"-449") [VH (*Homo sapiens* IGHV1-3*01 (83%) –(IGHD)-IGHJ4*01)] [8.8.12] (1"-119") -*Homo sapiens* IGHG1*03 {CH1[R⁹⁷>K(216")], CH2[N⁶⁷>G(299")], CH3[T²⁶>S(368"), L²⁸>A(370"), Y⁶⁷>W(409")],} (120"-449") (222"-219")-disulfide with κ light chain anti *CD3* (1'"-219'"') [V-KAPPA (*Homo sapiens* IGKV4-1*01 (89%) –IGKJ1*01)] [12.3.8] (1'"-112'"') -*Homo sapiens* IGKC*01 (113'"-219'"'); produced in CHO cells (Source: WHO pINN list 122)

STRUCTURAL FORMULA

Heavy chain A

EVQLVESGPG	LVKPSETLSL	TCTVSGFSLT	RFGVHWVRQP	PGKGLEWLGV	50
IWRGGSTDYN	AAFVSRLTIS	KDNSKNQVSL	KLSSVTAADT	AVYYCSNHYY	100
GSSDYALDNW	GQGTILVTVSS	ASTKGPSVFP	LAPSSKSTSG	GTAALGCLVK	150
DYFPEPVTVS	WNSGALTSGV	HTFPAVLQSS	GLYSLSSVVT	VPSSSLGTQT	200
YICNVNHKPS	NTKVDKKEVP	KSCDKTHTCP	PCPAPELLGG	PSVFLFPPKP	250
KDTLMISRTP	EVTCVVVDVS	HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYG	300
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ	350
VYTLPPSREE	MTKNQVSLWC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTPEV	400
LDSGGSFFLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNHYT	QKSLSLSPGK	450

Light chain B'

DIQMTQSPSS	LSASVGDRVT	ITCKASQDVR	NLVVWFQQKP	GKAPKLLIYS	50'
GSYRYSQVPS	RFSGSGSGTD	FTLTISLQSP	EDFATYYCQQ	HYSPPYTFGQ	100'
GTKVEIKRTV	AAQSVFIAPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Heavy chain C''

EVQLVQSGAE	VKKPGASVKV	SCKASGFTFT	SYIIHWVRQA	PGQGLEWIGW	50''
IYPENDNTKY	NEKFKDRVTI	TADTSTSTAY	LELSSLRSED	TAVYYCARDG	100''
YSRYYPDYWG	QGTLLTVSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD	150''
YFPEPVTVSW	NSGALTSGVH	TFFPAVLQSSG	LYSLSSVVTV	PSSSLGTQTY	200''
ICNVNHHKPSN	TKVDKKVEPK	SCDKTHTCP	CPAPELLGGP	SVFLFPPKPK	250''
DTLMISRTPE	VTCVVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYGS	300''
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	350''
YTLPPSREEM	TKNQVSLSCA	VKGFYPSDIA	VEWESNGQPE	NNYKTTTPVL	400''
DSDGSEFLVS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPGK	449''

Light chain D''

DIVMTQSPDS	LAVSLGERAT	INCKSSQSL	NSRTRKNYLA	WYQQKPGQSP	50''
KLLIYWTSTR	KSGVDRFSG	SGSGTDFTLT	ISSLAEDVA	VYYCKQSFIL	100''
RTFGQGTQVE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LNNFYPREAK	150''
VQWKVDNALQ	SGNSQESVTE	QDSKDYSTYSL	SSTLTLSKAD	YEKHKVYACE	200''
VTHQGLSSPV	TKSFNRGEC				219''

Disulfide bridges location

22-95	22''-96''	23'-38'	23'''-94'''	134'-194'	139'''-199'''	146''-202''	147-203
214'-223	219''-222''	228''-229	231''-232	263''-323''	264-324	369''-427''	370-428

Glycosylation sites (N))

none

MOLECULAR FORMULA	C ₆₅₀₈ H ₁₀₀₆₃ N ₁₇₂₇ O ₂₀₂₇ S ₄₀
MOLECULAR WEIGHT	146.21 kDa
TRADEMARK	None as yet
SPONSOR	Genentech, Inc.
CODE DESIGNATIONS	RO7187797, BFCR4350A
<u>CAS</u> REGISTRY NUMBER	2249888-53-5
UNII	P86BHN01VE
WHO NUMBER	11258

gbk